ESMO World Congress on Gastrointestinal Cancer 2016

Oncology Meeting Resources

29 Jun - 02 Jul 2016, Barcelona, Spain

World GI 2016 Square Image

The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts from the ESMO World GI 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.





Format available

https://oncologypro.esmo.org/Meeting-Resour...e-open-label-randomized-phase-3-TAILOR-trial

Cetuximab in combination with chemotherapy (either FOLFIRI or FOLFOX) is a standard-of-care first-line treatment for patients with RAS wt mCRC. The addition of cetuximab to first-line FOLFIRI or FOLFOX...

Date: 29 Jun 2016
Presenter: S. Qin
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...distance-in-exome-sequencing-of-colon-cancer

Carcinogenesis is considered to be an evolutionary process by natural selection of cell clones which have acquired advantageous heritable alterations. This occurrence, which resembles Darwin's evolutionary...

Date: 29 Jun 2016
Presenter: U. Popper
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...ma-mPDAC-previously-treated-with-gemcitabine

Patients with mPDAC frequently experience a significant symptom burden. This in turn negatively impacts their QoL. Nal-IRI, a nanoliposomal formulation of irinotecan, was evaluated with or without 5...

Date: 29 Jun 2016
Presenter: R. Hubner
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...endocrine-tumors-q-US-population-based-study

Small (≤2cm) pancreatic neuroendocrine tumors (PNETs) are a unique subset of pancreatic neoplasms. Chromogranin A levels (CgA), mitotic rate, and histologic grade are often used to characterize PNET...

Date: 29 Jun 2016
Presenter: K. Mirkin
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...on-adenocarcinoma-a-single-center-experience

Ramucirumab is a VEGFR-2 antibody that has proven to prolong overall survival (OS) in patients with pretreated metastatic gastric/gastrooesophageal junction (GEJ) adenocarcinoma.

Date: 29 Jun 2016
Presenter: U. Vogl
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...in-the-treatment-of-hepatocellular-carcinoma

Unresectable hepatocellular carcinoma (HCC) is one of the tumors with worst prognosis, with five-year survival rates lower than 20%. Sorafenib is a multikinase inhibitor with antiproliferative and...

Date: 29 Jun 2016
Presenter: P. Salamanca
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...-from-a-gastrointestinal-GI-tract-malignancy

Brain metastasis from a primary GI tumour is rare with reported incidences of less than 10% (1). In the era of advanced diagnostic imaging modalities and improved systemic therapies in GI cancers, the...

Date: 29 Jun 2016
Presenter: P.S. Lim
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...the-experience-of-a-Portuguese-cancer-center

Capecitabine-temozolomide (CAPTEM) is a treatment option in patients with advanced neuroendocrine tumors. In vitro data indicate that the combination of capecitabine (CAP) and temozolomide (TEM) is...

Date: 29 Jun 2016
Presenter: A. Chaves
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...r-GIC-a-case-control-study-and-meta-analysis

The sign of Leser-Trélat (SLT) includes the existence of ESK and cancer simultaneously. However, there is little evidence to support this association. Our objective was to evaluate the association...

Date: 29 Jun 2016
Presenter: J. Insuasty
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...metastasis-in-pancreatic-head-adenocarcinoma

Understanding and formulating an appropriate strategy for the para-aortic lymphadenectomy (LN16) during curative surgery for pancreatic head adenocarcinoma are still controversial.

Date: 29 Jun 2016
Presenter: D. Kostov
Resources: Abstract